Journal of Biomedical and Pharmaceutical Research Available Online at www.jbpr.in CODEN: - JBPRAU (Source: - American Chemical Society) NLM (National Library of Medicine): ID: (101671502) Index Copernicus Value 2021: 83.38 Volume 12, Issue 3, May -June: 2023, 23-33 ISSN (Online): 2279-0594 ISSN (Print): 2589-8752 23 | Page Research Article Formulation Development and Invitro Evaluation of Famotidine Gastroretentive Tablets Hrishabh Sharma, Ashutosh Sharma, Saurabh Pandey, Vikas Agarwal, Sunil Sain Jaipur College of Pharmacy, Jaipur, Rajasthan, India Article Info: Received: 28-03-2023 / Revised: 25-04-2023 / Accepted: 13-05-2023 DOI: https://doi.org/10.32553/jbpr.v12i3.992 Corresponding author: Hrishabh Sharma Conflict of interest statement: No conflict of interest Abstract: The present study involves the formulation and evaluation of gastroretentive drug delivery of Famotidine tablets. This type of drug delivery helps to retain the drug in the stomach. The swelling property of the formulation helps to retain the drug in the stomach, by swelling to such an extent so that cannot pass out of the stomach. Preformulation studies which include Organoleptic properties, Bulk and Tapped densities, Carr‘s index, Hausner‘s ratio, Melting point, pH, Solubility, were carried out are as per IP specifications. Drug-excipient compatibility studies were performed which shows that there is no interaction between drug and polymers. Evaluation studies have been performed for tablets include friability, hardness, weight variation, content uniformity, buoyancy studies are as per IP specifications. Drug release studies have been performed by using 0.1N HCl for 12 hrs. These studies have shown that the formulation F4 gave better drug release upto 12 hrs. which is formulated with HPMC K100 M. Introduction Dosage forms that can be retained in the stomach are called gastro retentive drug delivery system (GRDDS). GRDDS can improve the controlled delivery of drugs that have an absorption window by continuously releasing the drug for a prolonged period of time before it reaches its absorption site. Control of placement of a drug delivery system (DDS) in a specific region of the GI tract offers advantages for a variety of important drugs characterized by a narrow absorption window in the GIT or drugs with a stabilityproblem. (1) The need for gastro retentive dosage forms (GRDFs) has led to extensive efforts in both academia and industry towards the development of such drug delivery systems. These efforts resulted in GRDFs that were designed, in large part, based on the following approaches: (a) Low density form of the DF that causes buoyancy in gastric fluid.